MedTrace Logo

24-hour Ambulatory Blood Pressure Monitoring in Patients With Blood Pressure Above Thresholds in General Practice

NCT03774147 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1067

Last updated 2018-12-12

No results posted yet for this study

Summary

High blood pressure (HBP) is a major modifiable cardiovascular risk factor which prevalence is gradually increasing. Reducing blood pressure (BP) significantly decreases cardiovascular morbi-mortality. Nevertheless, BP control remains insufficient: only 51% of French patients using antihypertensive drugs achieve the BP control targets.

HBP is mostly diagnosed and managed in primary care. Nevertheless, office BP measurements are unreliable for BP control and poorer predict target organ damage. Ambulatory BP measurements are recommended for HBP diagnosis and follow-up. 24-hour ambulatory blood pressure monitoring (ABPM) is the most cost-effective strategy. Its superiority has been demonstrated for HBP diagnosis and cardiovascular prognosis.

In France, ABPM is poorly available and little studied in primary care. Therefore, the investigators conducted a regional prospective study to analyze the feasibility and benefits of ABPM among primary care hypertensive patients in daily practice.

Conditions

  • Hypertension
  • Blood Pressure Monitoring, Ambulatory
  • Primary Health Care

Interventions

DEVICE

24-hour Ambulatory Blood Pressure Monitoring (ABPM)

Sponsors & Collaborators

  • Association pour le Développement de la Recherche en Médecine Générale (ADRMG)

    collaborator UNKNOWN

  • Département de Médecine Générale de Dijon (DMG)

    collaborator UNKNOWN

  • University of Burgundy

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03774147 on ClinicalTrials.gov